CombiGene approved for listing on Nasdaq First North Stockholm and first day of trading is Wednesday 19 December 2018
Nasdaq Stockholm AB has decided that the shares and subscription warrants (TO2) of CombiGene AB (publ)
Nasdaq Stockholm AB has decided that the shares and subscription warrants (TO2) of CombiGene AB (publ)
To the Report >> "This is an English translation of the Swedish website; if there is
The units issued upon the board’s decision on 22 August 2018 consisted of both shares and
The subscription period for a preference share issue in CombiGene AB (“CombiGene” or “the Company”) amounting
CombiGene AB (publ) (”CombiGene” or ”the Company”) publishes this prospectus pursuant to a resolution by the
The Board of Directors of CombiGene AB (publ) (”CombiGene” or ”the Company”) has approved a proposal
Interim Report >> "This is an English translation of the Swedish website; if there is any
Read the report>> "This is an English translation of the Swedish website; if there is any
To the Annual Report >> "This is an English translation of the Swedish website; if there
Shareholders in CombiGene AB (publ) are hereby invited to attend the Annual General Meeting at 2.30